A Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study to Evaluate the Effect of Sacubitril-valsartan (LCZ696) Versus Enalapril on Changes in NT-proBNP and Safety and Tolerability of In-hospital Initiation of LCZ696 Compared to Enalapril in HFrEF Patients Who Have Been Stabilized Following Hospitalization for Acute Decompensated Heart Failure (ADHF).
Phase of Trial: Phase IV
Latest Information Update: 01 Apr 2018
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Enalapril
- Indications Decompensated heart failure
- Focus Therapeutic Use
- Acronyms PIONEER-HF
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 01 Apr 2018 Rationale and trial design published in the American Heart Journal.
- 16 Oct 2017 Planned End Date changed from 5 Apr 2018 to 29 Jun 2018.
- 16 Oct 2017 Planned primary completion date changed from 5 Apr 2018 to 29 Jun 2018.